Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Sparano, 2015, Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer, J Clin Oncol, 33, 2353, 10.1200/JCO.2015.60.9271 Liu, 2016, PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance), NPJ Breast Cancer, 2, 15023, 10.1038/npjbcancer.2015.23 Pan, 2017, 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years, N Engl J Med, 377, 1836, 10.1056/NEJMoa1701830 Albain, 2010, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, 11, 55, 10.1016/S1470-2045(09)70314-6 Symmans, 2007, Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol, 25, 4414, 10.1200/JCO.2007.10.6823 Symmans, 2017, Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype, J Clin Oncol, 35, 1049, 10.1200/JCO.2015.63.1010 Hatzis, 2011, A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer, J Am Med Assoc, 305, 1873, 10.1001/jama.2011.593 Symmans, 2010, Genomic index of sensitivity to endocrine therapy for breast cancer, J Clin Oncol, 28, 4111, 10.1200/JCO.2010.28.4273 Sinn, 2019, SET-ER/PR—a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer, NPJ Breast Cancer, 5, 16, 10.1038/s41523-019-0111-0 Cuzick, 2011, Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer, J Clin Oncol, 29, 4273, 10.1200/JCO.2010.31.2835 Haibe-Kains, 2012, A three-gene model to robustly identify breast cancer molecular subtypes, J Natl Cancer Inst, 104, 311, 10.1093/jnci/djr545 Lau, 2020, Technical validity of a customized assay of sensitivity to endocrine therapy using sections from fixed breast cancer tissue, Clin Chem, 66, 934, 10.1093/clinchem/hvaa105 Martin, 2005, Adjuvant docetaxel for node-positive breast cancer, N Engl J Med, 352, 2302, 10.1056/NEJMoa043681 Eiermann, 2011, Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial, J Clin Oncol, 29, 3877, 10.1200/JCO.2010.28.5437 Mackey, 2016, Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial, Ann Oncol, 27, 1041, 10.1093/annonc/mdw098 Sestak, 2018, Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial, JAMA Oncol, 4, 545, 10.1001/jamaoncol.2017.5524 Prat, 2013, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134 Karn, 2010, Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer, Breast Cancer Res Treat, 120, 567, 10.1007/s10549-009-0416-z Park, 2016, Adaptive randomization of neratinib in early breast cancer, N Engl J Med, 375, 11, 10.1056/NEJMoa1513750 Rugo, 2016, Adaptive randomization of veliparib-carboplatin treatment in breast cancer, N Engl J Med, 375, 23, 10.1056/NEJMoa1513749 Albain, 2016, Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 TRIAL, Cancer Res, 76 Yee, 2017, Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial, Cancer Res, 77 Chien, 2020, MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial, J Clin Oncol, 38, 1059, 10.1200/JCO.19.01027 Forero, 2017, Abstract P6-11-02: efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial, Cancer Res, 77 Consortium, 2020, Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial, JAMA Oncol, 6, 1355, 10.1001/jamaoncol.2020.2535 Sgroi, 2013, Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population, Lancet Oncol, 14, 1067, 10.1016/S1470-2045(13)70387-5 Hudis, 2007, Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system, J Clin Oncol, 25, 2127, 10.1200/JCO.2006.10.3523 Pocock, 2002, Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls, Lancet, 359, 1686, 10.1016/S0140-6736(02)08594-X Johnston, 2020, Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE), J Clin Oncol, 38, 3987, 10.1200/JCO.20.02514 Mayer, 2021, Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 22, 212, 10.1016/S1470-2045(20)30642-2 Lau, 2019, Reproducibility of the sensitivity to endocrine therapy (SET) assay for stage II/III breast cancer within and between pathology laboratories, Lab Invest, 99, 87